Encompass Health Corporation (NYSE:EHC) Shares Sold by M&T Bank Corp

M&T Bank Corp lowered its stake in Encompass Health Corporation (NYSE:EHC) by 18.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,274 shares of the company’s stock after selling 728 shares during the period. M&T Bank Corp’s holdings in Encompass Health were worth $332,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of EHC. Signaturefd LLC lifted its stake in Encompass Health by 21.6% during the fourth quarter. Signaturefd LLC now owns 704 shares of the company’s stock worth $65,000 after purchasing an additional 125 shares during the last quarter. Arlington Trust Co LLC raised its holdings in shares of Encompass Health by 22.9% during the first quarter. Arlington Trust Co LLC now owns 671 shares of the company’s stock valued at $68,000 after acquiring an additional 125 shares during the period. Merit Financial Group LLC grew its holdings in shares of Encompass Health by 4.1% during the first quarter. Merit Financial Group LLC now owns 4,220 shares of the company’s stock valued at $427,000 after buying an additional 166 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Encompass Health by 6.7% during the first quarter. Sequoia Financial Advisors LLC now owns 2,727 shares of the company’s stock worth $276,000 after acquiring an additional 172 shares in the last quarter. Finally, Benjamin Edwards Inc. increased its holdings in Encompass Health by 3.9% in the fourth quarter. Benjamin Edwards Inc. now owns 6,545 shares of the company’s stock worth $605,000 after buying an additional 247 shares during the last quarter. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Up 0.3%

Shares of Encompass Health stock opened at $110.28 on Friday. The firm’s 50 day moving average price is $119.18 and its 200-day moving average price is $106.70. The company has a market cap of $11.12 billion, a P/E ratio of 22.78, a PEG ratio of 2.23 and a beta of 0.88. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.81. Encompass Health Corporation has a 52-week low of $82.74 and a 52-week high of $123.13.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, April 24th. The company reported $1.37 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.18. Encompass Health had a net margin of 8.97% and a return on equity of 17.63%. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same period in the previous year, the firm earned $1.12 earnings per share. Encompass Health’s quarterly revenue was up 10.6% compared to the same quarter last year. On average, sell-side analysts predict that Encompass Health Corporation will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st were issued a $0.17 dividend. The ex-dividend date of this dividend was Tuesday, July 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.62%. Encompass Health’s payout ratio is 14.05%.

Wall Street Analyst Weigh In

A number of brokerages have commented on EHC. UBS Group raised their price objective on Encompass Health from $117.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, April 28th. Royal Bank Of Canada increased their target price on Encompass Health from $110.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, April 28th. Barclays upped their target price on Encompass Health from $118.00 to $129.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. KeyCorp upped their price target on Encompass Health from $122.00 to $135.00 and gave the company an “overweight” rating in a research report on Tuesday, May 27th. Finally, Wall Street Zen lowered Encompass Health from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $131.50.

Insider Buying and Selling

In other news, CEO Mark J. Tarr sold 118,384 shares of the company’s stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total value of $14,387,207.52. Following the transaction, the chief executive officer owned 527,070 shares in the company, valued at $64,054,817.10. This represents a 18.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP John Patrick Darby sold 10,000 shares of Encompass Health stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total value of $1,147,900.00. Following the sale, the executive vice president directly owned 79,710 shares in the company, valued at $9,149,910.90. The trade was a 11.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 132,663 shares of company stock valued at $16,034,082. 2.00% of the stock is currently owned by corporate insiders.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.